HUM-MOLGEN events: Psychiatric Drug Discovery & Development

HUM-MOLGEN -> Events -> Meetings and Conferences

Psychiatric Drug Discovery & Development

April 22, 2003

The Westin Princeton at Forrestal Village, Princeton NJ
June 23-24, 2003

This meeting is the first to comprehensively cover the latest approaches to CNS discovery & the development of psychopharmacologic therapies for the treatment of schizophrenia, depression, bipolar disorder & anxiety.

Dopaminergic, glutamatergic, serotonergic as well as neuropeptides will be discussed along with the impact of genomics, by industry leading scientists and clinicians. Organized for the industrial scientist/executive interested in CNS, psychopharmacology, or psychiatry!

KEYNOTE ADDRESS:

Genes to Targets: Dissecting Genetic Mechanisms of Psychosis

Daniel R. Weinberger, M.D.
Chief, Clinical Brain Disorders Branch, IRP
NATIONAL INSTITUTE OF MENTAL HEALTH, NIH

FEATURING:

-NMDA Receptor Modulation: A Valid Target for Anti-Schizophrenic Drugs
Joseph T. Coyle, M.D.
Department of Psychiatry
HARVARD MEDICAL SCHOOL AND MCLEAN HOSPITAL

- PreClinical Profile of Selective Serotonin-Norepineprine Reuptake Inhibitor, Duloxetine and Relevance to Depression & Persistent Pain
Smriti Iyengar, Ph.D.
Senior Scientist, Neuroscience Research
ELI LILLY & COMPANY

- The Antidepressant and Anxiolytic Action of
Substance P [NK1 receptor] Antagonists
Karen Maubach, Bsc(Hons) D.Phil.
Research Fellow
MERCK SHARP & DOHME

SECTIONS INCLUDE:

- Target Identification & Validation
- The Impact of Genomics on the Discovery of Novel Psychotherapeutics
- Novel mGlu, 5-HT and DA Receptor Agonists & Antagonists
- Neuropeptides and Imaging

Organized by:

Strategic Research Institute

Invited Speakers:

PRESENTATIONS BY:

Acadia Pharmaceuticals
AstraZeneca
Aventis
Axaron Biosciences AG
Eli Lilly & Company
Harvard Medical School and McLean Hospital
Johnson and Johnson
Lexicon Genetics, Inc.
Maryland Psychiatric Research Center
Merck & Company
Merck Sharp & Dohme
National Institute of Mental Health/NIH
Pfizer
Psychiatric Genomics, Inc.
Sanofi-Synthelabo
Synaptic Pharmaceutical Corporation
Wyeth Research